Arvinas Inc. (ARVN) Prices 4.545M Share Common Offering at $22/Sh

Arvinas, Inc. (NASDQ: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the pricing of an underwritten public offering of 4,545,455 shares of its common stock at a price of $22.00 per share, before underwriting discounts and commissions. In addition, Arvinas has granted the underwriters an option for a period of 30 days to purchase up to an additional 681,818 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares are being offered by Arvinas.

Goldman Sachs & Co. LLC, Citigroup and Piper Jaffray & Co. are acting as joint book-running managers for the offering. The offering is expected to close on or about November 12, 2019, subject to customary closing conditions.

You May Also Be Interested In

• Citi cuts TJX Companies rating to Neutral, lowers price target
• Singularity Future Technology prices $5M direct offering at $3.20 per share
• Robert Beck joins Encore Capital Group board of directors